Healthcare Services

Vitreoretinal Disorder Market Growth Driven by Rising Diabetic Retinopathy Cases

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Vitreoretinal Disorder Market Over The 2026–2030 Period?

The vitreoretinal disorder market size has demonstrated strong growth in recent years. It is anticipated to expand from $4.63 billion in 2025 to $4.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.9%. This historical growth can be linked to factors such as the rising prevalence of diabetic eye diseases, the increased availability of optical coherence tomography, a surge in ophthalmic surgical procedures, the expansion of specialty eye clinics, and advancements in diagnostic accuracy.

The vitreoretinal disorder market is projected to experience substantial growth in the upcoming years, with its size expected to reach $6.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This expansion during the forecast period is attributed to several factors, including the increasing demand for personalized retinal treatments, rising investments in ophthalmic innovation, the expansion of minimally invasive surgical techniques, the growing use of AI-driven diagnostics, and an increasing focus on vision preservation therapies. Key trends anticipated in the forecast period encompass the increasing adoption of advanced retinal imaging techniques, a rising use of minimally invasive vitreoretinal surgery, the growing integration of AI-based diagnostic tools, the expansion of targeted retinal therapies, and an enhanced focus on early disease detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23574&type=smp

What Key Factors Are Shaping The Vitreoretinal Disorder Market Landscape?

The increasing occurrence of diabetic retinopathy is projected to drive the expansion of the vitreoretinal disorder market moving forward. This eye condition develops from damage to the blood vessels within the retina, caused by elevated blood sugar levels in individuals with diabetes. The rise in diabetic retinopathy cases stems from the increasing prevalence of diabetes, often attributed to sedentary lifestyles and inadequate blood sugar control, which in turn leads to damage to retinal blood vessels. Vitreoretinal disorder management plays a critical role in treating diabetic retinopathy by addressing complications such as vitreous hemorrhage and tractional retinal detachment, thereby preserving vision and preventing further retinal damage. For instance, in October 2024, figures from the Australian Institute of Health and Welfare, an Australia-based government agency, showed that in 2022–23, 1.8% of screened First Nations people in Australia received treatment for diabetic retinopathy, with their age-standardized treatment rate of 1.3% being lower than that for non-Indigenous Australians at 1.5%. Hence, the escalating incidence of diabetic retinopathy is a key factor propelling the growth of the vitreoretinal disorder market.

Which Segments Define The Vitreoretinal Disorder Market Segment Structure?

The vitreoretinal disorder market covered in this report is segmented –

1) By Type: Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Other Types

2) By Diagnosis: Digital Fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Other Diagnosis

3) By Treatment: Surgery, Medication, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Retinal Tear: Atrophic Retinal Tear, Operculated Retinal Tear, Horseshoe Retinal Tear, Giant Retinal Tear

2) By Retinal Detachment: Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Exudative Retinal Detachment

3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema

4) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration

5) By Macular Hole: Full-Thickness Macular Hole, Lamellar Macular Hole, Tractional Macular Hole

6) By Other Types: Epiretinal Membrane, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinitis Pigmentosa, Uveitis, Vitreous Hemorrhage, Macular Edema, Central Serous Retinopathy, Proliferative Vitreoretinopathy

What Market Trends Are Affecting The Vitreoretinal Disorder Market?

Leading companies in the vitreoretinal disorder market are increasingly focusing on developing innovative products, such as continuous delivery drug solutions, to reduce the frequency of injections and improve patient outcomes. These continuous delivery drug solutions are medical systems designed to provide a sustained, controlled release of medication directly into the eye, thereby helping to lessen the need for frequent injections, maintain consistent therapeutic levels, and enhance patient adherence and visual results. For instance, in February 2025, Roche, a Switzerland-based global pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for Susvimo (ranibizumab injection) 100 mg/mL, which is a Port Delivery System intended for diabetic macular edema (DME). Susvimo facilitates continuous ranibizumab delivery through a refillable implant, enabling patients to sustain their vision with as few as two treatments per year, a significant improvement compared to the previous requirement of monthly eye injections. This system was thoroughly evaluated in the Phase III Pagoda study, which demonstrated sustained improvements in visual acuity and a safety profile consistent with prior approvals for neovascular age-related macular degeneration (nAMD). Susvimo’s innovative platform effectively reduces the treatment burden, improves patient convenience, and addresses the rising global prevalence of DME.

Who Are The Established Players Within The Vitreoretinal Disorder Market?

Major companies operating in the vitreoretinal disorder market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Carl Zeiss Meditec AG, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical, Apellis Pharmaceuticals Inc., Genentech Inc., Oxurion NV, Adverum Biotechnologies Inc., Opthea Limited, Graybug Vision Inc., Kiora Pharmaceuticals Inc., Allegro Ophthalmics Inc., Lineage Cell Therapeutics Inc., Ocugen Inc.

Get The Full Vitreoretinal Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report

Which Region Dominates The Vitreoretinal Disorder Market By Market Share?

North America was the largest region in the vitreoretinal disorder market in 2025. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vitreoretinal Disorder Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report

Browse Through More Reports Similar to the Global Vitreoretinal Disorder Market 2026, By The Business Research Company

Retinal Disorder Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Vitrectomy Devices Market Report

https://www.thebusinessresearchcompany.com/report/vitrectomy-devices-global-market-report

Optic Nerve Disorders Treatment Market Report

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795